| Revenue growth | Revenue +17% YoY, +13% QoQ to ₹1,430 Cr; Ex-US-led. |
|---|---|
| Margins | Gross margin 56.0% (vs 57.8%); EBITDA margin 17.6% (vs 19.0%) YoY. |
| Order book | Strong B2B US order book; new wins; no order book/execution ratio disclosed. |
| Demand visibility | Ex-US demand healthy; US shortages normalised; H2 launches 4–6 products expected. |
| Management confidence | Balanced: FY28 ambition 'intact' but US timeline slipped beyond FY28. |
Growth
Revenue +17% YoY, +13% QoQ; Ex-US +31% vs US +9%; EBITDA +8% YoY to record ₹251 Cr. Growth is Ex-US led.
Outlook
Management expects H2 stronger than H1, with 4–6 US launches and H2 finance cost of ₹40–45 Cr. The US $375M aspiration now lands a little beyond FY28, and FY27 capex is about ₹300 Cr.
Risks
Gross margin 56.0% (from 57.8%); net debt/EBITDA 1.72x; cash cycle 137 days; US controlled-substance quota constraints.
Last quarter's promises, checked
Delivered
- Guided Ex-US to grow faster than company avg → Ex-US +31% vs company +17% (= BEAT)
Partly delivered
- Guided 10 US launches to 31-Mar-27 → 3 in Q2 + 4–6 H2 expected (= PARTIAL)
Missed
- Guided gross margin 58–60% → 56.0% (= MISS)
- Guided Sandoz close in Q2 → close expected Q3 (= MISS)
- Guided US $375M by FY28 → now a little beyond FY28 (= MISS)
Earnings Call Transcript filed with BSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,037.30
- Market cap
- ₹9,562 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 15.5×Sector 47.2×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.